Prostate Cancer: Molecular Oncology Tumor Boards

This free case-based activity includes a crowd-sourced discussion of a 66-year-old male with a history of controlled hypertension that developed increased lower urinary tract symptoms while undergoing urologic evaluation. Also noted was a PSA elevated to 10.8 ng/ml. A sextant prostate needle biopsy procedure was then performed. 5/6 biopsies are diagnosed with prostatic adenocarcinoma. The histopathological features were not those of typical microacinar prostatic adenocarcinoma. Rather, approximately 65% of the cancer had a tubulopapillary architecture formed from glandular tumor cells, which were large and composed of pseudostratified columnar epithelium with markedly atypical nuclei with clumped chromatin and prominent nucleoli. This is most compatible with ductal prostatic adenocarcinoma.


Originally posted on a forum in the ASCO Connection, users now have the opportunity to claim CME, completion, or participation certificates for completing this activity.

Learning Objectives

  • Describe patterns of response and progression in metastatic castration resistant prostate cancer
  • Discuss common molecular alterations in prostate cancer
  • Recognize conditions in which immunotherapy is a treatment option in prostate cancer

Continuing Education Credit

1 Credit/Point is available for participation in this course. Certificate and credit types available include:

  • AMA PRA Category 1 Credits™
  • ABIM MOC Points
  • CNE Contact Hours
  • CPE Credits
  • Certificate of Participation may be used to confer credit; however, all final decisions regarding the awarding of credits will be made by the licensing organization to which the credits are submitted.
  • Certificate of Completion may be used to document participation, but no credit will be conferred.

Important Note: This course expires on October 25, 2020. Participants must complete all necessary course components by this date to receive credit.